Exelixis (EXEL) announced results from an expansion cohort of the phase 1b/2 STELLAR-001 trial evaluating zanzalintinib alone or in combination with atezolizumab in patients with previously-treated metastatic colorectal cancer. The findings will be presented during Poster Session C: Cancers of the Colon, Rectum and Anus on January 25 at the American Society of Clinical Oncology 2025 Gastrointestinal Cancers Symposium. Grade 3/4 treatment-related adverse events occurred in 40% of patients receiving zanzalintinib alone and 48% of patients receiving zanzalintinib in combination with atezolizumab. One grade 5 treatment-related AE occurred in each group, both of which were also determined by investigator as related to the disease under study. Zanzalintinib was discontinued in 19% of patients receiving zanzalintinib alone and 30% of patients receiving zanzalintinib in combination with atezolizumab. Treatment-related AEs leading to discontinuation of any drug occurred in 8% and 19% of patients, respectively.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis reports on subgroup analysis of Phase 3 CABINET study
- Exelixis downgraded to Perform from Outperform at Oppenheimer
- Exelixis downgraded to Perform at Oppenheimer on zanzalintinib concerns
- Jefferies has two ‘contradictory’ conclusions after Exelixis abstract release
- Exelixis falls after ASCO releases colorectal cancer data